Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tretinoin - Roche

Drug Profile

Tretinoin - Roche

Alternative Names: Acnisdin Retinoico; All-trans retinoic acid; Arotinoid; Avita; Dermojuventus; Loderm Retinoico; NSC 122758; Retinoic acid; Retirides; Vesanoid; Vitamin A acid; Vitamin-A Acid; Vitanol

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bertek Pharmaceuticals; Ortho-McNeil; Roche
  • Developer Roche
  • Class Antiacnes; Antineoplastics; Cyclohexenes; Keratolytics; Retinoids; Small molecules
  • Mechanism of Action Protein synthesis inhibitors; Retinoic acid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute promyelocytic leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acne; Acne vulgaris; Acute promyelocytic leukaemia; Photodamage; Warts
  • Discontinued Emphysema

Most Recent Events

  • 20 Apr 2017 Tretinoin licensed to OncBioMune Pharmaceuticals in Mexico, Central America and Latin America
  • 10 Mar 2017 Vitel Laboratorios has been acquired by OncBioMune Pharmaceuticals
  • 03 Nov 2016 Vesanoid® sub-licensed to Vitel Laboratorios in Mexico
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top